Comparison of the Beverage Hydration Index of Different Solutions

Inclusion Criteria

• •body mass index (BMI) \<35 kg/m2 (not morbidly obese)
• •Cannot have a sensitivity or be allergic to any components of the study product they will be excluded.
• •non-tobacco user
• •cannot be following a specialized dietary pattern that may alter findings (e.g., low carbohydrate/ketogenic diet, carnivore diet, intermittent fasting etc.)
• •willing to replicate the same dietary intake/activity (exercise) level for each day before a lab visit excluding screening
• •Will consume a minimum of 2 liters (women) or 2.5 liters (men) of water per day, on each day prior to experimental lab visits (excluding screening)
• •Will arrive to lab for visits euhydrated (USG 1.005-1.020)
• •Will not consume alcohol-containing beverages within 24 hours of testing
• •Will not consume caffeine-containing beverages within 12 hours of testing
• •can fast (consume water/treatments only) for 15 hours (10 hours prior to lab visits not including screening)
• •avoid strenuous activity for 24 hours prior to study visits excluding screening
• •Will not have a history or presence of a clinically relevant (that required or requires treatment) cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, biliary, gastrointestinal, pancreatic, or neurologic disorder (reviewed by Nurse practitioner)
• •Will not have other conditions that is likely to alter fluid balance or be negatively affected by changing electrolyte levels/hydration status (as determined by Nurse practitioner)
• •Is not consuming any medication which may alter fluid retention/electrolyte levels such as sodium-glucose co-transporter 2 (SGLT2) inhibitor (for type 2 diabetes), laxatives, diuretics, Apremilast, chemotherapy, or lithium. (Medications will be reviewed by Nurse practitioner)
• •Will not consume nutritional supplements, performance enhancing drugs, and/or non-steroidal anti-inflammatory drugs within 7 days of study visits excluding screening.
• •cannot be enrolled in another clinical study within 30 days of the first study visit
• •without active infection or illness of any kind